ATE429922T1 - Topische gel-abgabesysteme zur behandlung von hauterkrankungen - Google Patents

Topische gel-abgabesysteme zur behandlung von hauterkrankungen

Info

Publication number
ATE429922T1
ATE429922T1 AT01957238T AT01957238T ATE429922T1 AT E429922 T1 ATE429922 T1 AT E429922T1 AT 01957238 T AT01957238 T AT 01957238T AT 01957238 T AT01957238 T AT 01957238T AT E429922 T1 ATE429922 T1 AT E429922T1
Authority
AT
Austria
Prior art keywords
treatment
delivery systems
skin diseases
topical gel
gel delivery
Prior art date
Application number
AT01957238T
Other languages
German (de)
English (en)
Inventor
Gordon Dow
Robert Lathrop
Debra Dow
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24535786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE429922(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Application granted granted Critical
Publication of ATE429922T1 publication Critical patent/ATE429922T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01957238T 2000-08-03 2001-07-24 Topische gel-abgabesysteme zur behandlung von hauterkrankungen ATE429922T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/632,508 US6387383B1 (en) 2000-08-03 2000-08-03 Topical low-viscosity gel composition
PCT/US2001/023341 WO2002011683A1 (en) 2000-08-03 2001-07-24 Topical gel delivery system

Publications (1)

Publication Number Publication Date
ATE429922T1 true ATE429922T1 (de) 2009-05-15

Family

ID=24535786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01957238T ATE429922T1 (de) 2000-08-03 2001-07-24 Topische gel-abgabesysteme zur behandlung von hauterkrankungen

Country Status (24)

Country Link
US (2) US6387383B1 (OSRAM)
EP (2) EP1304992B1 (OSRAM)
JP (1) JP4988129B2 (OSRAM)
KR (2) KR100840169B1 (OSRAM)
CN (2) CN1460013B (OSRAM)
AR (1) AR030093A1 (OSRAM)
AT (1) ATE429922T1 (OSRAM)
AU (2) AU7900201A (OSRAM)
BE (1) BE2013C060I2 (OSRAM)
BR (1) BR0113247A (OSRAM)
CA (1) CA2417646C (OSRAM)
CY (3) CY1109189T1 (OSRAM)
DE (1) DE60138549D1 (OSRAM)
DK (2) DK2052714T3 (OSRAM)
ES (2) ES2326955T3 (OSRAM)
FR (1) FR14C0053I1 (OSRAM)
LU (1) LU92401I2 (OSRAM)
MX (1) MXPA03001006A (OSRAM)
PL (1) PL213237B1 (OSRAM)
PT (2) PT2052714E (OSRAM)
RU (1) RU2251410C2 (OSRAM)
SI (2) SI1304992T1 (OSRAM)
WO (1) WO2002011683A1 (OSRAM)
ZA (1) ZA200301037B (OSRAM)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
HUP0104424A3 (en) 1998-12-23 2002-12-28 Idea Ag Improved formulation for topical non-invasive application in vivo
DE69901284T2 (de) 1999-01-27 2002-11-28 Idea Ag Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
JP2004532853A (ja) 2001-05-09 2004-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 酒さを治療する目的での組成物の使用
US7368122B1 (en) * 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
KR20100055542A (ko) * 2002-06-25 2010-05-26 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
US20040167223A1 (en) * 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
US6906014B2 (en) * 2002-09-10 2005-06-14 Permatex, Inc. Stabilized topical composition
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
NZ541526A (en) 2003-01-24 2008-03-28 Stiefel Res Australia Pty Ltd Clindamycin phosphate foam
US20060135607A1 (en) * 2003-02-07 2006-06-22 Mochida Pharmaceutical Co., Ltd. Drug for improving prognosis for subarachnoid hemorrhage
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
BRPI0413558A (pt) 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
AU2003265624B2 (en) * 2003-08-21 2011-03-31 Abeona Therapeutics Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
RU2006105101A (ru) 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
CA2537763A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
US20050095245A1 (en) * 2003-09-19 2005-05-05 Riley Thomas C. Pharmaceutical delivery system
ATE378360T1 (de) * 2003-09-23 2007-11-15 Akciju Sabiedriba Solainfarms Polymere 3,5-dimethyl-1-adamantylammoniumsalze und deren verwendung in form von virustatika
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
JP5043435B2 (ja) 2003-10-03 2012-10-10 スリーエム イノベイティブ プロパティズ カンパニー アルコキシ置換イミダゾキノリン
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
JP2007511527A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
CN1906192A (zh) * 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
EP3205358A1 (en) * 2003-12-30 2017-08-16 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and method of using the same
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US7662855B2 (en) * 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
US20060014834A1 (en) * 2004-05-11 2006-01-19 Mohan Vishnupad Retinoid solutions and formulations made therefrom
US20050255131A1 (en) * 2004-05-11 2005-11-17 Mohan Vishnupad Clindamycin compositions and delivery system therefor
AU2005247467B2 (en) 2004-05-25 2010-12-02 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
ITMI20041376A1 (it) * 2004-07-09 2004-10-09 Uni Campus Bio Medico Di Roma Metodo di preparazione di un sistema polimerico biocompatibile per il rilascio farmacologico in uso topico e impieghi di detto sistema
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
EP2145618A1 (en) * 2004-11-09 2010-01-20 Imaginative Research Associates, Inc. Retinoid solutions and formulations made thereform
JP2008519784A (ja) * 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1863814A1 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008535832A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
MX2007013631A (es) * 2005-05-09 2008-01-24 Drugtech Corp Composiciones farmaceuticas de liberacion modificada.
ES2607454T3 (es) 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
JPWO2007023729A1 (ja) * 2005-08-23 2009-02-26 日産化学工業株式会社 徐放性製剤
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
BRPI0620907A2 (pt) * 2006-01-05 2011-11-29 Drugtech Corp composição farmacêutica, sistema de distribuição de droga vaginal e uso da composição farmacêutica
EA200870153A1 (ru) * 2006-01-05 2008-12-30 Драгтек Корпорейшн Композиция и способ ее использования
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
US20090053290A1 (en) * 2006-03-08 2009-02-26 Sand Bruce J Transdermal drug delivery compositions and topical compositions for application on the skin
ES2582654T3 (es) 2006-03-31 2016-09-14 Stiefel Research Australia Pty Ltd Gel en suspensión espumable
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
RU2309738C1 (ru) * 2006-08-28 2007-11-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав с противовоспалительным и обезболивающим действием и способ его получения
CN104606126A (zh) 2006-10-17 2015-05-13 纽沃研究股份有限公司 双氯芬酸凝胶
US8466128B2 (en) * 2007-01-30 2013-06-18 Cypress Pharmaceuticals, Inc. Hyaluronate compositions
US20080287373A1 (en) * 2007-05-17 2008-11-20 Popp Karl F Topical skin treating kits
US20080312245A1 (en) * 2007-06-12 2008-12-18 Longyan Xiao Methods and compositions for treating acne and other infectious diseases
JP2010539245A (ja) 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
WO2009051839A1 (en) * 2007-10-18 2009-04-23 Medicis Pharmaceutical Corporation Aqueous retinoid and benzoyl peroxide gel
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CA2704949A1 (en) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
CN101902913B (zh) 2007-12-21 2014-06-18 戈德玛实验室有限公司 手术前处理
US20090176719A1 (en) * 2008-01-07 2009-07-09 Liolabs Llc Compositions and methods for treating perioral dermatitis
MX2010010111A (es) * 2008-03-17 2010-12-15 Glenmark Pharmaceuticals Ltd Formulacion topica de dosis fija estable.
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
AU2009248046B2 (en) * 2008-05-16 2014-07-17 Galderma Research & Development Therapy regimen for treating acne related diseases
CN102056481A (zh) 2008-06-05 2011-05-11 陶氏制药科学公司 包含低浓度的在水和水混溶性有机溶剂中的悬浮液形式的过氧苯甲酰的局部药物制剂
EP2889028A1 (en) * 2008-06-24 2015-07-01 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
EP2440210A4 (en) * 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
EP3141246A1 (en) 2009-08-31 2017-03-15 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CA2792646C (en) 2010-03-26 2018-11-20 Galderma Research & Development Improved uses and compositions for safe and effective treatment of erythema
JP5747392B2 (ja) 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物
WO2012001064A2 (en) 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
ES2585847T3 (es) 2010-06-30 2016-10-10 Galderma Research & Development Utilización de un agonista del receptor adrenérgico alfa para prevenir o tratar un tumor de la piel
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
DK2444068T4 (en) 2010-10-21 2018-03-05 Galderma Sa Brimonide sub-composition
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
WO2013019974A1 (en) 2011-08-02 2013-02-07 Medicis Pharmaceutical Corporation Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea
CN103889417A (zh) 2011-10-19 2014-06-25 高德美国际公司 减少与全身使用5型磷酸二脂酶抑制剂有关的面部潮红的方法
WO2013057580A1 (en) 2011-10-19 2013-04-25 Galderma Pharma S.A. Method for treating capillary hemangiomas
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
RU2548714C2 (ru) * 2012-05-03 2015-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения угревой болезни и способ ее получения
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
RU2530644C2 (ru) * 2012-11-01 2014-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Противоугревая фармацевтическая композиция и способ ее получения
CN104995302B (zh) 2013-01-16 2021-08-31 爱默蕾大学 Cas9-核酸复合物及其相关用途
JP6453318B2 (ja) 2013-09-26 2019-01-16 ガルデルマ ソシエテ アノニム 委縮性皮膚瘢痕を治療するためのプロスタグランジンＦ２α及びその類似体
US10201481B2 (en) * 2014-03-07 2019-02-12 The Procter & Gamble Company Personal care compositions and methods of making same
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US9012402B1 (en) * 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
CN104473865A (zh) * 2014-11-17 2015-04-01 重庆华邦制药有限公司 地奈德凝胶剂及其制备方法
US20160235851A1 (en) 2015-02-17 2016-08-18 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
HUE050603T2 (hu) 2015-06-18 2020-12-28 Bausch Health Ireland Ltd Egy kortikoszteroidot és egy retinoidot tartalmazó topikális készítmények psoriasis kezelésére
US9707216B2 (en) 2015-07-13 2017-07-18 Dr. Reddy's Laboratories, Ltd. Topical retinoid compositions
CN106474059A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种质量更加稳定的地奈德洗剂
CN106474048A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种质量更加稳定的地奈德凝胶制剂
CN106474047A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种对光稳定的地奈德制剂
WO2017172761A1 (en) 2016-03-28 2017-10-05 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
WO2018213310A1 (en) 2017-05-15 2018-11-22 Cornell University Device and system for repairing intervertebral disc herniation and methods of use
US10779525B2 (en) 2018-01-16 2020-09-22 Zin Research LLC Treatment compound and method of application for hoof or foot disease in animals
US10653656B2 (en) 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
WO2020097211A1 (en) * 2018-11-06 2020-05-14 Cote Tim Topical compositions comprising pentoxifylline and methods of treatment using the same
FR3090385B1 (fr) * 2018-12-21 2021-01-08 Pf Medicament Composition émolliente sous forme d’émulsion
CN111743853A (zh) * 2019-03-29 2020-10-09 天津金耀集团有限公司 一种近中性丁酸氢化可的松的外用药物组合物
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
US20220202841A1 (en) * 2020-12-24 2022-06-30 Erine A. Kupetsky Dermatological formulations for treatment of dermatitis
JP2025501246A (ja) * 2021-12-28 2025-01-17 アーキュティス・バイオセラピューティクス・インコーポレーテッド 局所ロフルミラストエアゾールフォーム
KR20250024938A (ko) 2022-05-20 2025-02-20 덤바이온트, 인코포레이티드 피부 질환, 병태 및 장애의 예방, 치료 및 개선을 위한 pk 억제제의 사용을 위한 조성물 및 제제

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969516A (en) 1974-12-19 1976-07-13 Nelson Research & Development Company Composition and method for treatment of acne
US4497794A (en) 1980-12-08 1985-02-05 Dermik Laboratories, Inc. Erythromycin/benzoyl peroxide composition for the treatment of acne
US4361584A (en) 1977-10-07 1982-11-30 A.H.C. Pharmacal, Inc. Composition and method for the treatment of acne
US4247547A (en) 1979-03-19 1981-01-27 Johnson & Johnson Tretinoin in a gel vehicle for acne treatment
US4387107A (en) 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US4692329A (en) 1980-12-08 1987-09-08 William H. Rorer, Inc. Erythromycin/benzoyl peroxide antiacne compositions
LU83173A1 (fr) 1981-02-27 1981-06-05 Oreal Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion
US4514385A (en) 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
CH643138A5 (de) * 1983-08-29 1984-05-30 Mepha Ag Indomethacin enthaltende, gelartige salbe.
LU85111A1 (fr) 1983-12-01 1985-09-12 Oreal Composition anti-acnetique a base de peroxyde de benzoyle et d'au moins un filtre solaire
US4670254A (en) * 1983-12-09 1987-06-02 Toko Yakuhin Industry Co., Ltd. Gel preparations for topical application of diclofenac sodium
US5446028A (en) 1985-12-12 1995-08-29 Dermik Laboratories, Inc. Anti-acne method and composition
FR2604357B1 (fr) 1986-09-30 1988-12-02 Oreal Composition pharmaceutique et cosmetique anti-acneique
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
KR950003919B1 (ko) * 1987-03-20 1995-04-20 갈데르마 에스. 에이. 국소용 메트로니다졸 제제의 제조방법
MY105521A (en) * 1989-04-17 1994-10-31 Healthpoint Ltd Moisturizing vehicle for topical application of vitamin a acid.
EP0481007B1 (en) 1989-06-07 1997-01-22 BAZZANO, Gail S SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids
US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
GB9021320D0 (en) 1990-10-01 1990-11-14 Diomed Dev Ltd Compositions for topical application
US5380528A (en) 1990-11-30 1995-01-10 Richardson-Vicks Inc. Silicone containing skin care compositions having improved oil control
KR100244554B1 (ko) * 1991-10-16 2000-04-01 린다데이로하르 비이온성폴리아크릴아미드유도체를함유하는낮은ph의수성화장용겔
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
US5549914A (en) * 1992-12-14 1996-08-27 Sween Corporation Heat stable wound care gel
ES2160631T5 (es) 1993-07-01 2005-07-16 Yamanouchi Europe B.V. Utilizacion de agentes tensioactivos no ionicos en composiciones estables de retinoides para aplicacion topica.
US5482710A (en) 1993-07-30 1996-01-09 Chesebrough-Pond'usa Co., Division Of Conopco, Inc. Cosmetic composition for treatment of pimples and redness
US5382432A (en) 1993-11-15 1995-01-17 Elizabeth Arden Company, Division Of Conopco, Inc. Cosmetic method for treatment of skin
US5466446A (en) 1994-02-16 1995-11-14 Stiefel Laboratories, Inc. Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
EP0751789B1 (en) * 1994-03-21 2001-11-07 BROWN THOMSEN, John Gel for treatment of skin diseases and for disinfection of the skin
US5538732A (en) 1994-04-12 1996-07-23 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
US5451405A (en) 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
US5445823A (en) 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5750122A (en) 1996-01-16 1998-05-12 The Procter & Gamble Company Compositions for treating hair or skin
JP3193617B2 (ja) * 1996-01-29 2001-07-30 カネボウ株式会社 清涼感付与剤および人体用組成物
US5891451A (en) 1996-06-25 1999-04-06 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters
RU2119329C1 (ru) * 1996-06-26 1998-09-27 Акционерное общество открытого типа "Щелковское предприятие Агрохим" Основа для репеллентных кремов
FR2753626B1 (fr) * 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
JPH1179948A (ja) * 1997-09-12 1999-03-23 Noevir Co Ltd 養毛剤及び毛髪用化粧料、並びに皮脂分泌抑制用皮膚外用剤
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition

Also Published As

Publication number Publication date
PT2052714E (pt) 2013-10-17
SI2052714T1 (sl) 2013-11-29
JP2004505900A (ja) 2004-02-26
EP1304992A4 (en) 2006-11-02
US20020176891A1 (en) 2002-11-28
US6517847B2 (en) 2003-02-11
DK1304992T3 (da) 2009-08-10
BR0113247A (pt) 2003-06-24
EP2052714B1 (en) 2013-09-04
MXPA03001006A (es) 2005-02-25
ES2437321T3 (es) 2014-01-10
CN101305982B (zh) 2011-12-14
CN1460013B (zh) 2011-12-14
AU7900201A (en) 2002-02-18
PT1304992E (pt) 2009-07-20
EP1304992A1 (en) 2003-05-02
BE2013C060I2 (OSRAM) 2020-12-15
EP1304992B1 (en) 2009-04-29
CY1109189T1 (el) 2014-07-02
CN101305982A (zh) 2008-11-19
ES2326955T3 (es) 2009-10-22
ZA200301037B (en) 2004-02-09
WO2002011683A1 (en) 2002-02-14
SI1304992T1 (sl) 2009-10-31
EP2052714A1 (en) 2009-04-29
CY2014005I1 (el) 2014-07-02
JP4988129B2 (ja) 2012-08-01
PL213237B1 (pl) 2013-01-31
KR100840169B1 (ko) 2008-06-23
CN1460013A (zh) 2003-12-03
FR14C0053I1 (fr) 2014-08-08
CA2417646C (en) 2010-05-04
AU2001279002B2 (en) 2006-04-27
HK1125847A1 (en) 2009-08-21
KR20080036246A (ko) 2008-04-25
DE60138549D1 (de) 2009-06-10
CY1114646T1 (el) 2016-12-14
DK2052714T3 (da) 2013-10-14
PL360589A1 (pl) 2004-09-06
RU2251410C2 (ru) 2005-05-10
KR20030057526A (ko) 2003-07-04
AR030093A1 (es) 2003-08-13
CA2417646A1 (en) 2002-02-14
US6387383B1 (en) 2002-05-14
CY2014005I2 (el) 2015-12-09
LU92401I2 (fr) 2014-05-19

Similar Documents

Publication Publication Date Title
DE60138549D1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60232400D1 (de) Mittel zur linderung von hautreizungen
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
ATE371457T1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE455106T1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
DE60026704D1 (de) (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
CY2009002I1 (el) Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
DE69825447D1 (de) Gerät zur dermatologischen behandlung
FIU20060389U0 (fi) Luusairauksien hoito
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE60127552D1 (de) Intrakorporelle medikamente zur hoch-energetischen phototherapeutischen behandlung von krankheiten
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1304992

Country of ref document: EP